SCHEMBL20535686

SCHEMBL20535686

C[Si](C)(C)CCOCn1ccc2c(Sc3ccc(Cl)cc3)cccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 3/20 0.53
SLC6A4 P31645 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
EGFR P00533 1/20 0.32
IGF1R P08069 1/20 0.32
SRC P12931 1/20 0.32
FLT4 P35916 1/20 0.32
KDR P35968 1/20 0.32
FLT3 P36888 1/20 0.32
EPHB4 P54760 1/20 0.32
TEK Q02763 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
NPC1 O15118 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
DHFR P00374 1/20 0.32
FAAH O00519 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20535619 0.89 RHEB (0.41) RHEBSLC6A4PTGDR2EGFRIGF1R
SCHEMBL20535846 0.89 RHEB (0.41) RHEBSLC6A4PTGDR2NPC1FAAH
SCHEMBL23709778 0.86 RHEB (0.40) RHEBEGFRIGF1RSRCFLT4
SCHEMBL20535743 0.86 RHEB (0.40) RHEBEGFRIGF1RSRCFLT4
SCHEMBL20535778 0.85 RHEB (0.37) RHEBEGFRIGF1RSRCFLT4
SCHEMBL20535681 0.83 RHEB (0.41) RHEBPTGDR2LMNAGAANPC1
SCHEMBL20536171 0.81 ALDH1A1 (0.43) RHEBPTGDR2LMNANPC1MAPT
SCHEMBL20535513 0.80 RHEB (0.36) RHEBPTGDR2NPC1PTPN1MAPT
SCHEMBL15091003 0.74 NPC1 (0.39) EGFRIGF1RSRCFLT4KDR
SCHEMBL16450282 0.74 DGAT1 (0.38) SLC6A4EGFRIGF1RSRCFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS RHEB 1/4885SLC6A4 4819/4885PTGDR2 2650/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS RHEB 1/4885SLC6A4 4806/4885PTGDR2 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.